Zacks Investment Research·2d ago
Implied Volatility Surging for Phathom Pharmaceuticals Stock OptionsInvestors need to pay close attention to PHAT stock based on the movements in the options market lately.
PHAT's revenue has scaled from $7.3M in 2024Q2 to $84.7M in 2026Q3 with gross margins holding near 78% to 80%, and SG&A fell from $94.5M in 2025Q1 to $57.7M in 2026Q3, suggesting emerging operating leverage.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 29, 2026 | -$0.16-45.9% vs -$0.11 | $85M-0.1% vs $85M |
Q3 2026 Jul 30, 2026 | -$0.21-19.6% vs -$0.18 | $74M+1.4% vs $73M |
Q2 2026 Apr 30, 2026 | -$0.37-37.0% vs -$0.27 | $58M+4.3% vs $56M |
Q1 2026 Feb 26, 2026 | -$0.29+9.2% vs -$0.32 | $58M+0.7% vs $57M |
Investors need to pay close attention to PHAT stock based on the movements in the options market lately.
FLORHAM PARK, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following investor conferences: Guggenheim 3rd Annual Healthcare Innovation Conference in Boston, MA Date: Tuesday, November 10, 2026Fireside Chat: 3:00 p.m.
A Media Snippet accompanying this announcement is available by clicking on this link.
Phathom Pharmaceuticals NASDAQ: PHAT reported third-quarter 2026 revenue growth and a second consecutive quarter of positive operating profit excluding stock-based compensation, as the company continued efforts to expand access to its GERD treatment VOQUEZNA.
Benchmark PHAT against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Phathom Pharmaceuticals, Inc. (PHAT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $5.25 | $418.72M | -5.37 | 216.93% | -30.19% | — | — | |
| $21.23 | $3.64B | 10.28 | 11.87% | 30.13% | 28.03% | — | |
| $26.16 | $3.19B | 7.09 | 4.29% | 32.75% | — | — | |
| $15.85 | $2.19B | -1.25 | -2.75% | -43.27% | -68.13% | 7.26% | |
| $4.39 | $722.65M | 4.87 | -15.72% | 37.38% | — | — | |
| $132.04 | $8.49B | 27.67 | -89.41% | 62.04% | 42.83% | — |
Phathom Pharmaceuticals, Inc. (PHAT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Phathom Pharmaceuticals, Inc. (PHAT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Oct 29, 2026·SEC
Oct 26, 2026·SEC
Oct 23, 2026·SEC
Get notified when PHAT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Phathom Pharmaceuticals, Inc. (PHAT) stock FAQ — growth, dividends, profitability & financials explained
Phathom Pharmaceuticals, Inc. (PHAT) reported $274.9M in revenue over the trailing twelve months. Revenue was $175.1M in fiscal year 2025.
Phathom Pharmaceuticals, Inc. (PHAT) grew revenue by 86.8% over the trailing twelve months, compared with the twelve months before.
No. Phathom Pharmaceuticals, Inc. (PHAT) reported a net loss of $83.0M over the trailing twelve months.
Phathom Pharmaceuticals, Inc. (PHAT) had negative free cash flow of $20.6M over the trailing twelve months.
